Overview Request Sample Pages Request Customization Download PDF
You are viewing: France Ophthalmology Drugs Market analysis
Part of: Ophthalmology Drugs Market (Global)

The France Ophthalmology Drugs Market was valued at $459.1 Million in 2025 and projected to reach to $629 Million by 2030, representing a compound annual growth rate of 6.5%. France's ophthalmology drugs market is positioned for sustained growth through 2030, driven by demographic aging and increasing prevalence of vision-threatening conditions.

France Ophthalmology Drugs Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

France Ophthalmology Drugs Market Trends and Insights

  • This growth trajectory reflects France's aging population, rising prevalence of age-related eye conditions, and increasing healthcare investment in ophthalmic treatments.
  • France maintains a robust pharmaceutical infrastructure and strong regulatory framework that supports the development and commercialization of innovative eye care medications. The French ophthalmology drugs market benefits from high healthcare spending, advanced diagnostic capabilities, and widespread access to prescription medications through the country's universal healthcare system.
  • France's pharmaceutical sector continues to drive innovation in treatments for conditions such as dry eye disease, glaucoma, age-related macular degeneration, and diabetic retinopathy.
  • Between 2025 and 2030, France is expected to see sustained demand for both established and novel ophthalmic therapies, supported by favorable reimbursement policies and growing patient awareness of eye health..

Key Market Statistics

  • CAGR (2025-2030) 6.5% CAGR
  • Market Size, 2025 ~USD 459.1 Million
  • Forecast, 2030 ~USD 629 Million
  • Country France

France Ophthalmology Drugs Market Overview

Market Valuation :

France's ophthalmology drugs market is valued at USD 459.1 million in 2025, with strong growth momentum driven by increased healthcare spending and pharmaceutical innovation in ophthalmic treatments.

Aging Population Impact :

France's demographic shift toward an older population is driving higher prevalence of age-related macular degeneration, cataracts, and glaucoma, creating sustained demand for specialized ophthalmic medications.

Healthcare Infrastructure :

France's advanced healthcare system and robust reimbursement policies support widespread adoption of premium ophthalmic drugs, ensuring patient access to cutting-edge treatments across public and private sectors.

Growth Trajectory :

With a projected CAGR of 6.5% through 2030, the market is expected to reach USD 629.0 million, outpacing the global average of 6.1% and reflecting France's commitment to ophthalmic care excellence.

France Ophthalmology Drugs Market Dynamics

  • The country's well-established healthcare infrastructure and favorable reimbursement environment support continued pharmaceutical innovation and market expansion.
  • Rising awareness of preventive eye care and early diagnosis initiatives further bolster market potential.
  • France's pharmaceutical sector continues to invest in advanced ophthalmic therapies, including biologics and targeted treatments for retinal diseases.
  • Government healthcare policies prioritizing chronic disease management ensure consistent demand for ophthalmic medications across both urban and regional healthcare facilities..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • SANOFI
  • Pfizer Inc.
  • NOVARTIS

    Key Takeaways

    • France's ophthalmology drugs market is valued at USD 459.1 million in 2025 and will reach USD 629.0 million by 2030, growing at 6.5% CAGR.
    • France's aging demographic and high prevalence of age-related eye diseases drive sustained demand for ophthalmic medications.
    • France's universal healthcare system and favorable reimbursement policies support consistent market growth and patient access to treatments.
    • Innovation in treatments for dry eye disease, glaucoma, and retinal conditions positions France as a key market for advanced ophthalmology drugs.

    Ophthalmology Drugs Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment FARICIMAB (Molecule)
    Forecast Period 2025–2030
    Growth Rate CAGR of 6.1% from 2025 to 2030
    Largest Segment INTRAVITREAL (Route Of Administration)
    Market Size Base Year (Billions) ~USD 19.55 (2025)
    Revenue Forecast (Billions) ~USD 26.28 (2030)
    Segments Covered Molecule, Modality, Indication, Type, Route Of Administration, End User

    France Ophthalmology Drugs Market Report Segmentation

    6 segment dimensions are covered across the global market.

    By Molecule

    • Aflibercept
    • Faricimab
    • Other Molecules
    • Ranibizumab

    By Modality

    • Monoclonal Antibodies & Fusion Proteins
    • Other Modalities
    • Small Molecules

    By Indication

    • Age-Related Macular Degeneration
    • Diabetic Macular Edema
    • Diabetic Retinopathy
    • Other Indications

    By Type

    • Dry Amd
    • Wet Amd

    By Route Of Administration

    • Intravitreal
    • Other Routes Of Administration
    • Topical

    By End User

    • Hospitals
    • Long-Term Care Facilities
    • Specialty Centers

    FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    HOSPITALS543.1499529.6561.8599637675.6717.96.3
    LONG-TERM CARE FACILITIES110.7103.1109.1115.5122.7130.2137.7145.96
    SPECIALTY CENTERS49.541.643.445.247.449.551.553.84.4
    TOTAL703.3643.7682.1722.5769.1816.7864.8917.66.1

    Target Audience

    • Pharmaceutical Companies : Manufacturers and distributors of ophthalmic drugs need France-specific market data to optimize product launches, pricing strategies, and market penetration in this high-value European market.
    • Healthcare Investors : Investment firms and venture capitalists require detailed France market analysis to evaluate portfolio opportunities, assess growth potential, and make informed funding decisions in the ophthalmic sector.
    • Medical Device & Biotech Firms : Companies developing innovative eye care solutions need France market intelligence to understand demand patterns, competitive positioning, and regulatory pathways for product commercialization.
    • Healthcare Consultants : Strategy consultants advising healthcare clients require France-specific market data to develop competitive strategies, market assessments, and business recommendations for ophthalmic stakeholders.
    • Government & Policy Makers : French healthcare authorities and policymakers need market insights to inform healthcare budgeting, reimbursement policies, and strategic planning for ophthalmic care delivery and drug accessibility.

    Key Companies in the France Ophthalmology Drugs Market

    CompanyHQOwnershipStrongest segments
    REGENERON PHARMACEUTICALS INC.United StatesPublic CompanyOphthalmology (EYLEA franchise),Immunology / Inflammation (Dupixent, Kevzara),Oncology / Hematology (Libtayo, bispecifics pipeline),
    BAYER AGGermanyPublic CompanyCrop Science (seeds, traits, crop protection, digital ag, services),Pharmaceuticals (cardiology, women’s health, oncology, hematology, ophthalmology, imaging, cell & gene),Consumer Health (OTC, self-care, supplements, dermatology, pain, digestive),
    NOVARTIS AGSwitzerlandPublic CompanyOncology and Hematology (Kisqali, Tafinlar+Mekinist, Pluvicto, Lutathera, Scemblix, Promacta/Revolade, Jakavi, Fabhalta),Cardiovascular, Renal and Metabolic (Entresto, Leqvio and related CVRM portfolio),Immunology and Neuroscience (Cosentyx, Xolair, Ilaris and related assets),
    ABBVIEUnited StatesPublic CompanyImmunology (Skyrizi, Rinvoq and related),Oncology/Hematology (Imbruvica, Venclexta, Epkinly, Elahere, Emrelis),Neuroscience & CNS (Vraylar, Duodopa, Vyalev, migraine portfolio),
    APELLIS PHARMACEUTICALSUnited StatesPrivate CompanySYFOVRE – Geographic Atrophy,EMPAVELI – PNH and related indications,Pipeline and collaborations (APL-3007, APL-9099, Beam partnership),
    BIOGENUnited StatesPublic CompanyMultiple sclerosis franchise (TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, OCREVUS-related),SMA and rare neurology (SPINRAZA, SKYCLARYS, QALSODY, zorevunersen pipeline linkage),Alzheimer’s and psychiatry (LEQEMBI, ZURZUVAE),
    BAUSCH + LOMBCanadaPublic CompanyVision Care (contact lenses, lens care, OTC eye care, vitamins),Pharmaceuticals (Rx and generic ophthalmics),Surgical (cataract, corneal, vitreous, retinal devices and IOLs),
    ASTELLAS PHARMA INC.JapanPublic CompanyOncology (XTANDI, XOSPATA, VYLOY, PADCEV),Urology (Betanis/Myrabetriq/BETMIGA),Immunology / Transplant (Prograf),
    FORMYCON AGGermanyPublic CompanyRanibizumab biosimilars (ophthalmology),Aflibercept biosimilars (ophthalmology),Ustekinumab biosimilar pipeline/early revenues,
    BIOCONIndiaPublic CompanyBiosimilars (oncology, diabetes, immunology),Generics and APIs,CRDMO (discovery, development, manufacturing services),
    SANDOZ GROUP AGSwitzerlandPublic CompanySmall-molecule generics (oral and injectable),Biosimilars,Specialty and rare disease off-patent medicines,
    SANTEN PHARMACEUTICAL CO., LTD.JapanPublic CompanyGlaucoma & ocular hypertension therapies,Dry eye & keratoconjunctival disease,Allergic conjunctivitis & inflammatory eye disease,
    INNOVENTChinaPublic CompanyOncology immunotherapy (PD-1, CTLA-4, combinations),Oncology targeted therapies and cell therapy,Autoimmune and ophthalmology biologics,
    OUTLOOK THERAPEUTICS, INC.United StatesPublic CompanyONS-5010 (ophthalmic bevacizumab for wet AMD and retinal diseases),Other pipeline / platform and collaboration-derived income,

    REGENERON PHARMACEUTICALS INC.

    Regeneron Pharmaceuticals Inc. is a United States-based public pharmaceutical company founded in 1988 with 15,343 employees. The company focuses on the discovery, development, and commercialization of medicines.

    BAYER AG

    Bayer AG is a German public company founded in 1863 with 87,757 employees, operating across pharmaceuticals, consumer health, and agricultural sciences. The company is one of the world's largest diversified life sciences organizations.

    NOVARTIS AG

    Novartis AG is a Swiss public pharmaceutical company founded in 1996 with 75,267 employees. The company develops and manufactures a broad range of innovative medicines and healthcare products.

    ABBVIE

    AbbVie is a United States-based public pharmaceutical company founded in 2012 with 57,000 employees. The company discovers, develops, and markets pharmaceutical products across multiple therapeutic areas.

    APELLIS PHARMACEUTICALS

    Apellis Pharmaceuticals is a United States-based private biopharmaceutical company founded in 2009 with 736 employees. The company focuses on the development of novel therapeutic candidates.

    BIOGEN

    Biogen is a United States-based public biotechnology company founded in 1978 with 7,500 employees. The company discovers, develops, manufactures, and delivers medicines primarily in neurology and immunology.

    BAUSCH + LOMB

    Bausch + Lomb is a Canadian public company founded in 1853 with 13,000 employees specializing in eye health and vision care products. The company is a global leader in the eye care industry.

    ASTELLAS PHARMA INC.

    Astellas Pharma Inc. is a Japanese public pharmaceutical company founded in 1923 with 14,099 employees. The company researches, develops, and commercializes pharmaceutical products worldwide.

    FORMYCON AG

    Formycon AG is a German public biopharmaceutical company founded in 1999 with 203 employees. The company specializes in the development of biosimilar medicines.

    BIOCON

    Biocon is an Indian public biopharmaceutical company founded in 1978 with 16,447 employees. The company develops and manufactures biopharmaceuticals, including biosimilars and small molecule drugs.

    SANDOZ GROUP AG

    Sandoz Group AG is a Swiss public pharmaceutical company founded in 1886 with 22,356 employees. The company is a global leader in generic and biosimilar medicines.

    SANTEN PHARMACEUTICAL CO., LTD.

    Santen Pharmaceutical Co., Ltd. is a Japanese public pharmaceutical company founded in 1890 with 3,968 employees. The company specializes in ophthalmic and other pharmaceutical products.

    INNOVENT

    Innovent is a Chinese public biopharmaceutical company founded in 2011 with 7,502 employees. The company focuses on the research and development of innovative biologics.

    OUTLOOK THERAPEUTICS, INC.

    Outlook Therapeutics, Inc. is a United States-based public biopharmaceutical company founded in 2010 with 17 employees. The company develops and commercializes ophthalmic therapeutic products.

    Reasons to Buy this Report

    • Market-Specific Sizing Data : Access precise valuation figures for France's ophthalmology drugs market with detailed 2025-2030 projections, enabling accurate financial planning and investment decisions tailored to the French market.
    • Competitive Landscape Analysis : Understand France-specific competitive dynamics, key pharmaceutical players, market share distribution, and strategic positioning within the French ophthalmic drugs sector.
    • Regulatory & Reimbursement Insights : Gain comprehensive knowledge of French healthcare regulations, ANSM approval processes, HAS reimbursement criteria, and pricing strategies specific to the French market environment.
    • Growth Driver Identification : Identify France-specific growth catalysts including demographic trends, disease prevalence patterns, healthcare policy changes, and emerging treatment categories driving market expansion.
    • Strategic Market Entry Planning : Develop informed market entry strategies with France-focused insights on distribution channels, healthcare provider relationships, patient demographics, and localized commercial opportunities.

    Frequently asked questions

    What is the current size of France's ophthalmology drugs market?

    France's ophthalmology drugs market is valued at USD 459.1 million in 2025.

    What is the projected market size for France's ophthalmology drugs by 2030?

    France's ophthalmology drugs market is projected to reach USD 629.0 million by 2030.

    What is the growth rate of France's ophthalmology drugs market?

    France's ophthalmology drugs market is expected to grow at a CAGR of 6.5% from 2025 to 2030.

    What factors are driving growth in France's ophthalmology drugs market?

    Growth in France is driven by an aging population, rising prevalence of age-related eye conditions, strong healthcare infrastructure, favorable reimbursement policies, and increasing innovation in ophthalmic treatments.

    Which eye conditions are most prevalent in France's ophthalmology drugs market?

    France's market is dominated by treatments for age-related macular degeneration, glaucoma, dry eye disease, and diabetic retinopathy.

    RESEARCH METHODOLOGY

    This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global ophthalmology drugs market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

    Secondary Research

    Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the ophthalmology drugs market. The secondary sources used for this study include US Food and Drug Administration (US FDA), European Medicines Agency (EMA), World Health Organization (WHO), National Center for Biotechnology Information (NCBI), White papers, Company Websites, Interviews with Experts, Annual Reports, SEC Filings, Investor Presentations, and MarketsandMarkets Analysis. These sources also obtained key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

    Primary Research

    A comprehensive primary research was undertaken following an initial assessment of the global ophthalmology drugs market landscape through secondary research. This involved conducting in-depth interviews with market experts from the demand side, including stakeholders from hospitals, long-term care facilities, and specialty centers. Additionally, interviews were held with key supply-side participants, such as C-suite and senior executives, product managers, and marketing and sales leaders from prominent manufacturers, distributors, and channel partners. The research covered six major geographical regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while 30% involved demand-side experts. Data collection methods included structured questionnaires, email correspondence, online surveys, personal interviews, and telephonic discussions to understand the market dynamics comprehensively.

    The following is a breakdown of the primary respondents:

    Ophthalmology Drugs Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Both bottom-up and top-down approaches were used to estimate and validate the total size of the ophthalmology drugs market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • A list of the major global players operating in the ophthalmology drugs market was generated.
    • The revenues generated from their ophthalmology drug products have been determined through annual reports and secondary sources (including paid databases).
    • The products were mapped according to the segments of the market. Percentage shares and splits were determined based on the revenue contributed to each segment. This was verified using secondary sources and by industry experts.
    • All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.

    Global Ophthalmology Drugs Market Size: Bottom-up and Top-down Approaches

    Ophthalmology Drugs Market

    Data Triangulation

    After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    Ophthalmology drugs are specifically designed to treat or prevent eye diseases and disorders. These medications target various parts of the eye, including the cornea, conjunctiva, lens, retina, and optic nerve. The market includes a range of effective therapies across different drug modalities, such as biologics and biosimilars (e.g., anti-VEGF drugs, monoclonal antibodies, oligonucleotides, and peptides), small molecules, gene therapy, and cell therapy. These treatments address various conditions, including age-related macular degeneration (AMD), diabetic retinopathy, diabetic macular edema, retinal vein occlusion, uveitis, and neurotrophic keratitis, among others.

    Stakeholders

    • Pharmaceutical & biotechnology companies
    • Hospitals
    • Patient advocacy organizations
    • Specialty clinics
    • Long-term care facilities
    • Academic researchers and government research organizations
    • Private research institutes
    • Contract manufacturing organizations (CMOs)
    • Contract research organizations (CROs)
    • Venture capitalists    

    Report Objectives

    • To define, describe, and forecast the ophthalmology drugs market by molecule, modality, route of administration, indication, end user, and region
    • To provide detailed information regarding the factors influencing market growth (such as drivers, opportunities, restraints, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall ophthalmology drugs market
    • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
    • To profile the key players in the global ophthalmology drugs market as well as comprehensively analyze their core competencies and market rankings
    • To forecast the size of the market segments in North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
    • To track and analyze competitive developments, such as product launches & approvals, expansions, acquisitions, partnerships, product pipelines, collaborations, and agreements, in the ophthalmology drugs market

     

    Get the Full Ophthalmology Drugs Market Report

    Full forecast, segment splits, and company analysis for all Ophthalmology Drugs Market.

    Download Sample Pages Buy Report

    METHODOLOGY

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    Cite this Research
    DMCA.com Protection Status